Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study

BACKGROUND: Savolitinib, a selective MET inhibitor, showed efficacy in patients with non-small cell lung cancer (NSCLC), including pulmonary sarcomatoid carcinoma (PSC), harbouring MET exon 14 skipping alteration (METex14). OBJECTIVE: To analyse post hoc, the association between circulating tumour D...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yongfeng, Ren, Yongxin, Fang, Jian, Cao, Lejie, Liang, Zongan, Guo, Qisen, Han, Sen, Ji, Zimei, Wang, Ye, Sun, Yulan, Chen, Yuan, Li, Xingya, Xu, Hua, Zhou, Jianying, Jiang, Liyan, Cheng, Ying, Han, Zhigang, Shi, Jianhua, Chen, Gongyan, Ma, Rui, Fan, Yun, Sun, Sanyuan, Jiao, Longxian, Jia, Xiaoyun, Wang, Linfang, Lu, Puhan, Xu, Qian, Luo, Xian, Su, Weiguo, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629582/
https://www.ncbi.nlm.nih.gov/pubmed/36339926
http://dx.doi.org/10.1177/17588359221133546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629582/
https://www.ncbi.nlm.nih.gov/pubmed/36339926
http://dx.doi.org/10.1177/17588359221133546

Ejemplares similares